Androgenic function of the gonads in males with hyperthyroidism

The aim of the study was to examine the levels of sex hormones in men with hyperthyroidism before and during treatment, and determining the feasibility of testosterone prescribing together with thyrostatic therapy, in men with androgen deficiency. The study involved 37 men with newly diagnosed diffuse toxic goiter and 16 healthy men, aged from 22 to 55 years. The testosterone (test.) fractions (overall and free), SHBG, LH, FSH, estradiol and prolactin were determined. All hormones were measured before treatment and after 3, and then 6 months of thyrostatic ther apy. The overall test. level in men with hyperthyroidism was the same as in healthy subjects. Absolute and relative content of free test. fraction was significantly lower, but the SHBG level was higher than in healthy age relative men. The diagnostics of androgen deficiency syndrome was based on free test. determination. All patients with Diffuse toxic goiter the tiamazol (Merkazolil) was appointed, while treatment with testosterone (Omnadren250) were offered to patients with low of free test. levels, but not all followed the recommendations. The groups were follow: patients without androgen deficiency ( n = 16), patients with androgen deficiency, taking only thyrostatic therapy ( n = 10), patients with androgen deficiency taken thyrostatic therapy simultaneously with testosterone therapy ( n = 11). The decreasing of free test. level was detected in 57% of examined men. In most cases (80%) of that patients the 6 months thyrostatic therapy did not lead to free test. normalization. The free test. level concentration was nor mal only in 2 examined not receiving testosterone men (20%) and in 9 (82%; χ 2 = 5.76; p = 0.017) among those who recieved both: thyrostatic and testosterone therapy. During treatment with Omnadren250 the relative content of free test. was significantly higher at 3 and 6 months of treatment. Using a questionnaire AMS confirmed the dynamics characteristics of androgen deficiency in men with hyperthyroidism during treatment. Thus, the recom mendation of prescribing testosterone simultaneously with the start of thyrostatic therapy are grounded in androgen deficiency men with hyperthyroidism.

males, hyperthyroidism, androgen deficiency, treatment

1. Дедов И.И., Калиниченко С.Ю. Возрастной андрогенодефицит у мужчин. М.: Практическая медицина, 2006. 240 с.

2. Buvat J., Maggi M., Guay A., Torres L.O. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J. Sex. Med. 2013; 10 (1): 245–284.

3. Daig I., Heinemann L.A.J., Kim S. et al. The aging male symptoms (AMS) scale: rewiew of its methodological characteristics. Health Qual. Life Outcomes. 2003; 1: 1–12.

4. Gordon G.G., Southern A.L., Tochimoto S. et al. Effect of hyperthy roidism and hypothyroidism on the metabolism of testosterone and androsterone in man. J. Clin. Endocrinol. Metab. 1969; 29: 164–171.

5. Hudson R.W., Edwards A.L. Testocular function in hyperthy roidism. J. Androl. 1992; 13: 117–124.

6. Jockenhovel F., Schubert M. Male hypogonadism. 2nd ed. UNI MED Verlag AG, 2007. 192 p.

7. Kidd S.G., Glass A.R., Vigensky R.A. The hypothalamicpituitary testicular axis inthyrotoxicosis. J. Clin. Endocrinol. Metab. 1979;48: 798–802.

8. Krassas G.E., Pontikides N. Male reproductive function in relation with thyroid alteration. Best. Pract. Res. Clin. Endocrinol. Metab. 2004; 18 (2): 183–195.

9. Krassas G.E., Tziomalos K., Papadopolou F. et al. Erectile dysfunc tion in patients with hyper and hypothyroidism: how common and should we treat. J. Clin. Endocrinol. Metab. 2008; 93 (5): 1815–1819.

10. MendisHandagama S.M., Siril Ariyaratne H.B. Leidig cells, thy roid hormones and steroidogenesis. Ind. J. Experim. Biol. 2005;43: 939–962.

11. Nieschlag E., Swerdloff R., Behre H.M. et al. Investigation, treat ment and monitoring of lateonset hypogonadism in males. ISA, ISSAM, and EUA recommendations. Int. J. Androl. 2005; 28: 125–127.

12. Nisula B.C., Loriaux D.L., Wilson Y.A. Solid phase method for measurement of binding capacity of testosteroneestradiol globulin in human serum. Steroids. 1978; 31: 681–687.

13. Oppenheimer J.H., Schwartz H.L., Surks M.I. Tissue different in the concentration of triiodthyronine nuclear binding sites in rat: liver, kidney, pituitary, heart, brain, spleen, and testeis. Endocrinol. 1974; 95: 897–903.

14. Visser W.E., Friesema E.C., Jansen J., Visser T.J. Thyroid hormone transport in and out of cells. Trends Endocrinol. Metab. 2008; 19 (2): 50–56.